Senores Pharmaceuticals Limited was originally incorporated as ‘Senores Pharmaceuticals Private Limited’ under the Companies Act, 2013 through certificate of incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre. The name of the Company was thereafter changed to ‘Senores Pharmaceuticals Limited’ upon conversion to a public limited company pursuant to a Board resolution dated August 1, 2023, a special resolution passed in the extraordinary general meeting of the Shareholders held on August 24, 2023 and the approval of the central government dated September 4, 2023, and consequently a fresh certificate of incorporation dated September 4, 2023, was issued by the RoC to reflect the change in name.

Senores Pharmaceuticals is global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of US, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Its strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing it as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, it strategically identifies commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets. 

It leverages its R&D capabilities to develop and manufacture a portfolio of differentiated complex pharmaceutical products. Its focus on quality and its ability to identify specialty and complex molecules has resulted in a pipeline of curated complex products spanning diverse dosage forms and therapeutic domains, demonstrated through its partnerships in the Regulated Markets of US, Canada and United Kingdom with foreign and Indian pharmaceutical companies.

Products of the company

Marketed Products

ANDA Products

• Acetaminophen Butalbital and Acetaminophen Butalbital Caffeine
• Chlorzoxazone
• Diclofenac potassium
• Ketorolac
• Mexiletine Hydrochloride

Sourced Products

Awards, accreditations and recognitions

• 2022: Its subsidiary, RPPL, obtained the ISO 9001:2015 certification in the ‘general’ section.
• 2022: Its Subsidiary, RPPL, obtained the ISO 9001:2015 certification in the ‘B-lactum’ section.
• 2023: Its Subsidiary, RPPL, received the WHO-GMP certificate from the FDA in the ‘manufacturer’ category.
• 2023: Its Subsidiary, RPPL, received the GLP certificate from the FDA.
• 2024: The Atlanta Facility of its Subsidiary, Havix, was audited and approved by the USFDA.

History and milestones

• 2021: Incorporated a wholly owned subsidiary, Senores Pharmaceuticals Inc in the US.
• 2021: Entered into a new segment of API with acquisition of Ratnagene Lifescience Private Limited.
• 2022: Started the domestic business with a launch of the critical care injectables.
• 2023: Acquired majority stake in Havix., making it a Subsidiary of the company
• 2023: Consolidated its presence in emerging markets by acquiring shares in Ratnatris Pharmaceuticals Private Limited, making a subsidiary of the company.
• 2024: Launched first CMO product in the US with Jubilant Cadista.